Qiagen (NYSE:QGEN – Free Report) – Investment analysts at Zacks Research dropped their Q1 2025 EPS estimates for Qiagen in a report released on Monday, September 4th. Zacks Research analyst M. Mondal now expects that the company will earn $0.57 per share for the quarter, down from their prior estimate of $0.58. The consensus estimate for Qiagen’s current full-year earnings is $2.07 per share.
Qiagen (NYSE:QGEN – Get Free Report) last issued its earnings results on Tuesday, August 8th. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.01. Qiagen had a net margin of 17.04% and a return on equity of 13.72%. The firm had revenue of $497.00 million during the quarter, compared to analyst estimates of $492.21 million. During the same quarter in the prior year, the business earned $0.51 earnings per share. Qiagen’s revenue for the quarter was down 8.6% on a year-over-year basis.
View Our Latest Research Report on QGEN
Qiagen Price Performance
QGEN stock opened at $42.58 on Wednesday. Qiagen has a 52 week low of $40.38 and a 52 week high of $51.18. The company has a quick ratio of 1.96, a current ratio of 2.36 and a debt-to-equity ratio of 0.38. The company has a fifty day simple moving average of $45.16 and a two-hundred day simple moving average of $45.47. The firm has a market capitalization of $9.71 billion, a P/E ratio of 28.97, a price-to-earnings-growth ratio of 10.79 and a beta of 0.37.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Park Place Capital Corp purchased a new position in Qiagen in the 2nd quarter worth about $31,000. WealthPLAN Partners LLC purchased a new position in Qiagen in the 1st quarter worth about $33,000. Altshuler Shaham Ltd purchased a new position in Qiagen in the 2nd quarter worth about $37,000. Assetmark Inc. increased its stake in Qiagen by 41.6% in the 1st quarter. Assetmark Inc. now owns 834 shares of the company’s stock worth $38,000 after buying an additional 245 shares during the period. Finally, Captrust Financial Advisors increased its stake in Qiagen by 23.1% in the 1st quarter. Captrust Financial Advisors now owns 1,232 shares of the company’s stock worth $60,000 after buying an additional 231 shares during the period. Hedge funds and other institutional investors own 57.99% of the company’s stock.
About Qiagen
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Articles
- Five stocks we like better than Qiagen
- Investing in Agriculture 101: How to Invest in Agriculture
- These Quality Dividend Kings Grow their Dividends the Fastest
- What is Forex and How Does it Work?
- 3 Growth Stocks to Buy in September
- How Investors Can Identify and Successfully Trade Gap-Up Stocks
- 3 Underappreciated Stocks with Nowhere to Go But Up
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
